In the claims:

Please amend claims 13 and 14 as follows:

1. (original) An anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein(a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient

2. (original) The agent according to claim 1, wherein the LK68 gene comprises a nucleotide sequence represented by SEQ. ID. No. 1.

3. (original) The agent according to claim 1, wherein the gene carrier harboring the LK68 gene is a vector or a recombinant virus.

4. (original) The agent according to claim 3, wherein the vector is selected from a group consisting of a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

5. (original) The agent according to claim 3, wherein the recombinant virus is selected from a group consisting of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

6. (original) The agent according to claim 1, wherein the cells are selected from a group consisting of hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells.

7. (original) The agent according to claim 1, wherein the gene carrier is selected from a group consisting of pSecTag-LK68, pLXSN-LK68, rAAV-LK68 and pAAV-LK68.

8. (original) The agent according to claim 1, wherein the LK8 gene comprises a nucleotide sequence represented by SEQ. ID. No. 2.

9. (original) The agent according to claim 1, wherein the gene carrier harboring the LK8 gene is a vector or a recombinant virus.

10. (original) The agent according to claim 9, wherein the vector is selected from a group consisting of a linear DNA vector, a plasmid DNA vector and a recombinant viral vector.

11. (original) The agent according to claim 9, wherein the recombinant virus is selected from a group consisting of retrovirus, adenovirus, adeno-associated virus, herpes simplex virus and lentivirus.

12. (original) The agent according to claim 9, wherein the gene carrier is selected from a group consisting of pSecTag-LK8, pLXSN-LK8, rAAV-LK8 and pAAV-LK8.

13. (currently amended) The agent according to claim 3 ~~or claim 9~~, wherein the vector is included by 0.05 ~ 500 mg.

14. (currently amended)The agent according to claim 3 ~~or claim 9~~, wherein the recombinant virus is included by 10^3 - 10^{12} IU.

15. (original) The agent according to claim 1, wherein the cells are included by 10^3 - 10^8 e.a.

16. (original) The agent according to claim 1, wherein the cancer is selected from a group consisting of colon carcinoma, liver cancer, lung cancer, breast cancer, brain tumor, prostatic carcinoma, skin cancer, stomach cancer, pancreas cancer, lymphoma, kidney cancer, ovarian cancer and metastatic tumor.

17. (original) The agent according to claim 16, wherein the cancer is selected from a group consisting of colon carcinoma, liver cancer, lymphoma or metastatic tumor.

18. (original) A method for the prevention or the treatment of a solid tumor, which includes a step of parenteral administration of the agent for gene therapy of claim 1 to an individual.

19. (original) The method according to claim 18, wherein the prevention or the treatment of a solid tumor is accomplished by the inhibition of the growth and the metastasis of the solid tumor.

20. (original) The method according to claim 18, wherein the administration of a gene carrier harboring human apolipoprotein(a) kringle KIV9-KIV10-K V (LK68) or K V (LK8) gene is accomplished by a method selected from a group consisting of chemical method, physical method, conjugation using liposome, a method using receptor and virus, etc.

21. (original) The method according to claim 18, wherein the administration is characterized by injecting cells selected from a group consisting of hematopoietic stem cells, dendritic cells, autologous tumor cells and established tumor cells transfected with human apolipoprotein(a) kringle KIV9-KIV10-KV(LK68) or KV(LK8) gene to a patient.